Monte Rosa Therapeutics, Inc. (GLUE)
9.31
-1.00
(-9.70%)
USD |
NASDAQ |
Nov 12, 16:00
9.50
+0.19
(+2.04%)
After-Hours: 20:00
Monte Rosa Therapeutics Debt to Equity Ratio : 0.0731 for Sept. 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2026 | 0.0731 |
| June 30, 2026 | 0.078 |
| March 31, 2026 | 0.0748 |
| December 31, 2025 | 0.1682 |
| September 30, 2025 | 0.1634 |
| June 30, 2025 | 0.1534 |
| March 31, 2025 | 0.1521 |
| December 31, 2024 | 0.1916 |
| September 30, 2024 | 0.2127 |
| June 30, 2024 | 0.1974 |
| March 31, 2024 | 0.2962 |
| December 31, 2023 | 0.2568 |
| Date | Value |
|---|---|
| September 30, 2023 | 0.2514 |
| June 30, 2023 | 0.2201 |
| March 31, 2023 | 0.1894 |
| December 31, 2022 | 0.1732 |
| September 30, 2022 | 0.1569 |
| June 30, 2022 | 0.1614 |
| March 31, 2022 | 0.0214 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | -3.814 |
| December 31, 2020 | -1.391 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| United Therapeutics Corp. | 0.00 |
| ACADIA Pharmaceuticals, Inc. | 0.0518 |
| Alnylam Pharmaceuticals, Inc. | 0.8316 |
| Anika Therapeutics, Inc. | 0.1901 |
| Savara, Inc. | 0.2815 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 697.72M |
| Total Liabilities (Quarterly) | 201.52M |
| Shareholders Equity (Quarterly) | 496.21M |
| Current Ratio | 10.32 |
| Net Debt Paydown Yield | 0.10% |